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Abstract The ubiquitin proteasome system (UPS)
orchestrates the turnover of innumerable cellular proteins.
In the process of ubiquitination the small protein ubiquitin
is attached to a target protein by a peptide bond. The
ubiquitinated target protein is subsequently shuttled to a
protease complex known as the 26S proteasome and sub-
jected to degradative proteolysis. The UPS facilitates the
turnover of proteins in several settings. It targets oxidized,
mutant or misfolded proteins for general proteolytic
destruction, and allows for the tightly controlled and spe-
ciﬁc destruction of proteins involved in development and
differentiation, cell cycle progression, circadian rhythms,
apoptosis, and other biological processes. In neuropathol-
ogy, alteration of the UPS, or mutations in UPS target
proteins may result in signaling abnormalities leading to
the initiation or progression of tumors such as astrocyto-
mas, hemangioblastomas, craniopharyngiomas, pituitary
adenomas, and medulloblastomas. Dysregulation of the
UPS may also contribute to tumor progression by pertur-
bation of DNA replication and mitotic control mechanisms,
leading to genomic instability. In neurodegenerative dis-
eases caused by the expression of mutant proteins, the
cellular accumulation of these proteins may overload the
UPS, indirectly contributing to the disease process, e.g.,
sporadic Parkinsonism and prion diseases. In other cases,
mutationofUPScomponentsmaydirectlycausepathological
accumulation of proteins, e.g., autosomal recessive Parkin-
sonism and spinocerebellar ataxias. Defects or dysfunction
of the UPS may also underlie cognitive disorders such as
Angelman syndrome, Rett syndrome and autism, and muscle
and nerve diseases, e.g., inclusion body myopathy and giant
axon neuropathy. This paper describes the basic biochemical
mechanisms comprising the UPS and reviews both its theo-
reticalandproveninvolvementinneuropathologicaldiseases.
The potential for the UPS as a target of pharmacological
therapy is also discussed.
Abbreviations
A1Up Ataxin-1 interacting ubiquitin-like protein
APC Protein mutated in adenomatous polyposis
coli syndrome
APC/C Anaphase promoting complex/cyclosome
multimeric E3 ubiquitin ligase
BMP Bone morphogenic protein, an extracellular
patterning signal in CNS development
Cbl Casitas B-lineage lymphoma, a small family
of RING-type E3 ubiquitin ligases
CDK Cyclin-dependent kinase
CHIP Carboxy terminus of Hsc70-interacting
protein, a U-box E3 ubiquitin ligase
DUB Deubiquitination enzyme
E1 Ubiquitin activating enzyme
E2 Ubiquitin conjugating enzyme
E3 Ubiquitin ligase
EGFR Epidermal growth factor receptor
FTLD-U Frontotemporal lobar degeneration with
ubiquitin-positive inclusions
G76 Terminal glycine residue of ubiquitin
GSK3 Glycogen synthase kinase 3
HDM2 Human double minute 2, human MDM2
homolog, an E3 ubiquitin ligase for p53
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ubiquitin ligase
HIF-1a Hypoxia-inducible factor 1, alpha subunit
HSP70 Heat shock protein 70, a chaperone protein
and ATPase
HSP90 Heat shock protein 90, a chaperone protein
and ATPase
IBM Inclusion body myopathy
IBMPFD Hereditary inclusion body myopathy with
Paget disease of bone and frontotemporal
dementia
K48 Lysine 48 of ubiquitin
K63 Lysine 63 of ubiquitin
LRRK2 Leucine-rich repeat kinase-2
MAFbx Atrogin-1, a muscle-speciﬁc F-box ubiquitin
ligase adapter protein
MAP8 Microtubule-associated protein 8
MAP1B Microtubule-associated protein 1B
MDM2 Mouse double minute 2, an E3 ubiquitin
ligase for p53
NII Neuronal intranuclear inclusion
NCI Neuronal cytoplasmic inclusion
NEDD4 Neural precursor cell expressed
developmentally down-regulated 4, an E3
ubiquitin ligase
NEDD8 Neural precursor cell expressed
developmentally down-regulated 8, a small
ubiquitin-like posttranslational modiﬁer
protein
PIP3 Phosphatidylinositol (3,4,5)-trisphosphate
PMP22 Peripheral myelin protein 22
PTTG-1 Pituitary tumor transforming gene-1, securin,
an APC/C E3 ubiquitin ligase substrate
pVHL von Hippel–Lindau protein, an E3 ubiquitin
ligase substrate adaptor protein
SCF Skp/cullin/F-box E3 ubiquitin ligase complex
Shh A cholesterol-dependent extracellular
patterning signal in CNS development
STK15 Serine-threonine kinase 15, aurora A kinase,
an APC/C E3 ubiquitin ligase substrate
RASSF1A Ras association (RalGDS/AF-6) domain
family member 1
siRNAs Small interfering RNAs (ribonucleic acid
oligomers)
SUMO Small ubiquitin-like posttranslational
modiﬁer protein
TDP-43 TAR DNA binding protein 43
TRAF6 Tumor necrosis factor receptor associated
factor 6, a RING-type E3 ligase
TSG101 Tumor susceptibility gene 101
Ubc Ubiquitin conjugating enzyme (E2)
UBA Ubiquitin-associated domain
UBE3A E6AP, a HECT-type E3 ubiquitin ligase
UBL Ubiquitin-like domain
UCH-L1 Ubiquitin carboxy-terminal hydrolase L1,
a deubiquitination enzyme (DUB), and E3
ubiquitin ligase when dimerized
UPS Ubiquitin proteasome system
USP7 Ubiquitin speciﬁc protease 7, a
deubiquitinating enzyme (DUB), its targets
include ubiquitinated forms of p53, histones
and ataxin-1
VEGF Vascular endothelial growth factor
VHLD von Hippel–Lindau disease
Introduction
The ubiquitin proteasomal system (UPS) provides both a
precise and a general means for the cell to dispose of
biologically non-useful proteins, including mutant, mis-
folded, damaged, terminally modiﬁed or over-accumulated
proteins [44]. The ability of UPS to cause rapid substrate-
speciﬁc proteolysis also allows it to function as a molecular
switch in many signaling pathways, quickly turning off the
function of a target protein.
Ubiquitin is a small 8.5 kD protein composed of 76
amino acids. In the process of ubiquitination (also known
as ubiquitylation), ubiquitin is covalently attached to lysine
residues within target proteins via a peptide bond [44]. In
many cases, additional ubiquitin monomers are added to
the ﬁrst ubiquitin to form polyubiquitin chains consisting
of four to seven ubiquitin monomers. These polyubiquiti-
nated proteins are then shuttled to a multimeric protease
complex known as the 26S proteasome, present in both the
nucleus and cytoplasm of mammalian cells. At the pro-
teasome, ubiquitin monomers are released from the target
protein and recycled for future use. The target protein is
then degraded by proteasomal protease activity.
Ubiquitination is a multistep process
Aaron Ciechanover, Avram Hershko and Irwin Rose shared
the 2004 Nobel Prize in Chemistry for elucidating the
multistep process of ubiquitin-mediated protein degradation
[44]. Ubiquitin is ﬁrst activated by an E1 ubiquitin-acti-
vating enzyme (Fig. 1). This activation is ATP-dependent
and results in transient adenylation of ubiquitin. AMP is
then released and a thioester bond is formed between the
C-terminal carboxyl group of ubiquitin and a sulfhydryl
group on an E1 cysteine residue [41]. Ubiquitin is then
transferred to a cysteine residue of an E2 ubiquitin conju-
gating enzyme (Ubc). The ubiquitin-bound E2 Ubc then
330 Acta Neuropathol (2009) 118:329–347
123associates with an E3 ubiquitin ligase capable of recog-
nizing a speciﬁc target protein. The Ubc facilitates transfer
of activated ubiquitin to the E3 ligase–target protein
complex. The E3 ligase catalyzes the formation of an
isopeptide bond between a target protein lysine residue and
the C-terminal glycine of ubiquitin (Gly76). In rare cases,
the Ubc processes both E2 ubiquitin conjugating and E3
ubiquitin ligase activity.
A more recently described E4 activity has been attrib-
uted to at least two protein factors that facilitate
conjugation of additional ubiquitin monomers to form the
polyubiquitin chain, usually through linkages of lysine 48
[64]. Chains formed by linkages involving other lysine
residues in ubiquitin, particularly lysine 63, also occur,
as do chains with mixed lysine 48 and lysine 63 linkages.
The type of linkage, 48, 63, or mixed, affects the fate of
the ubiquitinated protein. K48-linked polyubiquitinated
proteins are generally degraded in the proteasome and
K63-linked polyubiquitinated proteins are ultimately
degraded in the lysosome [62, 123].
Another class of UPS proteins sometimes known as
shuttle or ubiquitin receptor proteins act as carriers to
deliver polyubiquitinated proteins to the 26S proteasome
[8, 55]. The 26S proteasome is composed of a 20S core
subunit capped by two 19S regulatory subunits, one at
either end of the cylindrically shaped core to form a barrel-
like structure [44]. The core subunit itself is composed of
four rings. Ubiquitin-associated (UBA) domains of the
ubiquitin receptor protein bind the polyubiquitin chains of
target proteins and ubiquitin-like (UBL) domains of the
receptor protein bind the 19S regulatory subunits of the
proteasome [8, 55]. Like E1-mediated ubiquitin activation,
transfer of the polyubiquitinated protein to the proteasome
is an ATP-dependent process.
Proteolytic degradation of the target protein takes place
within the rings of the core subunit following removal of
the ubiquitin monomers by deubiquitination enzymes
(DUBs) and unfolding of the substrate protein [44]. The
outer rings of the core act as gates to the core and each is
composed of seven a-subunits. The inner two rings contain
the protease activity and are each composed of seven
b-subunits.
Proteins with UBA domains also bind monoubiquiti-
nated proteins and are involved in initiating endocytosis
[62, 97]. These proteins may also protect monoubiquiti-
nated proteins from polyubiquitination or deubiquitination.
DUBs are thought to also act to deubiquinate ubiquitinated
proteins to prevent their targeting to the proteasome.
Ubiquitin receptor proteins effectively bind tetraubiquitin
chains and may also function to protect polyubiquitinated
proteins from unnecessary polyubiquitin chain expansion
or deubiquitination prior to reaching the proteasome [55].
Thus, the process of ubiquitination appears to be highly
regulated at various levels of the UPS.
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Fig. 1 Overview of the
ubiquitin proteasome system.
E1 ubiquitin activating enzymes
transfer activated ubiquitin
(aUb) to E2 ubiquitin
conjugating enzymes that
associate with E3 ubiquitin
ligases. E3 ubiquitin ligases
catalyze the formation of a
isopeptide bond between
ubiquitin (Ub) and the target
protein. Substrate recognition
often requires prior
phosphorylation (PO4) of the
target protein. E4 enzymes
promote the formation of
polyubiquitin chains. Receptor
proteins containing UBL and
UBA domains transfer the
polyubiquitinated target protein
to the proteasome for cleavage
in to free amino acids and small
peptides. Deubiquitinating
enzymes (DUBs) promote
recycling of ubiquitin
monomers for reactivation
by E1
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Nuclear and cytosolic proteins generally undergo poly-
ubiquitination and degradation by the 26S proteasome, as
do some membrane proteins [129]. Membrane proteins may
also be monoubiquitinated, triggering their cytoplasmic
internalization and degradation in either the endosome–
lysosome system or the proteasome [97]. Cbl is a plasma
membrane-associated E3 ligase that along with an E2 Ubc,
either monoubiquitinates or polyubiquitinates several
membrane proteins [74].
More recently, a family of ubiquitin-like modiﬁers
known as small ubiquitin-like modiﬁer (SUMO) 1-4 has
been described. These modiﬁers are small proteins similar
in size to ubiquitin. Through a process analogous to
monoubiquitination termed sumoylation, SUMO monomers
are conjugated to target proteins. In some cases mono-
ubiquitination or sumoylation may act to protect proteins
from ubiquitin-dependent degradation [59] and in other
cases they appear to trigger polyubiquitination [112].
Sumoylation and monoubiquitination at one or two lysines
within a target protein may also alter the subcellular loca-
tion of the protein [98]. Monoubiquitination of membrane
proteins may trigger their cytoplasmic internalization [97].
Monoubiquitination of the p53 tumor suppressor causes it to
be transported from the nucleus to the cytoplasm and
transport may be further enhanced by sumoylation of p53
[71].
An additional small ubiquitin-like posttranslational
modiﬁer is known as neural precursor cell expressed,
developmentally down-regulated 8 (NEDD8) [22]. The
functions of neddylation are less understood; however,
neddylation of cullin proteins, essential subunits of certain
E3 ubiquitin ligase complexes, appears to be required for
normal ligase function (Fig. 2).
Ubiquitination is substrate speciﬁc
E1 activity is nonspeciﬁc with regard to the protein targets
of the UPS and only two isoforms of this enzyme exist in
the cell (E1a and E1b) [18]. By comparison about 50 dif-
ferent E2s are known [10]. E3 ligases are the most variable
and abundant with over 500 putative E3s identiﬁed so far.
A given E2 can often associate with multiple different E3s
providing for a large variety of functional E2/E3 activities
and a relatively high degree of target substrate speciﬁcity.
However, this speciﬁcity is not absolute. Many E3 proteins
are able to ubiquitinate several, usually biochemically
related, substrate target proteins. These related proteins
often share a common small amino acid sequence that acts
as a relatively substrate-speciﬁc E3 binding domain. Many
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Fig. 2 Cbl family E3 ligases
and UBE3A E3 ligase are single
proteins that associate with an
E2 Ubc and the target substrate.
The SCF and APC/C E3
ubiquitin ligases are multimeric
complexes. The APC/C has only
two known adapter subunits,
Cdc20 and Cdh1 (not to be
confused with E-cadherin,
which is sometimes also
referred to as Cdh1). The SCF
can associate with several
different substrate adapter
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123target proteins are thought to be ubiquitinated by only one
E3, while others, the tumor suppressor p53 for example,
can be ubiquitinated by multiple E3s [71, 116, 141].
Most of the E3 ligases are classiﬁed as to whether they
contain homologous to E6AP COOH-terminus (HECT) or
really interesting new gene (RING) domains. A third
smaller class of E3 ligases is referred to as U-box containing
ligases. Both HECT and RING types may possess E3 ligase
function as single proteins, for example the HECT-type
ligase UBE3A and the RING-type ligase Cbl (Fig. 2).
RING-type E3s, however often associate with scaffolding
and other auxiliary proteins to form multimeric functional
complexes. These complexes can associate with different
regulatory subunits, which act as substrate-speciﬁc adaptor
proteins providing for even greater substrate speciﬁcity.
Examples include the Skp/cullin/F-box (SCF) and anaphase
promoting complex/cyclosome (APC/C) E3 ubiquitin liga-
ses that exhibit speciﬁcity for different substrates depending
on the adaptor protein bound to the complex (Fig. 2). SCF
complexes containing isoforms of the F-box protein b-TrCP
can ubiquitinate several proteins, including the DNA tran-
scriptionalregulatorb-cateninandthecellcycleprogression
regulator Emi1 [40, 43]. In some instances, substrate pro-
teins must be phosphorylated ﬁrst at speciﬁc sites before
they can be recognized by the E3 ubiquitin ligase. This may
provideanadditionallevelofcontrolastowhenandwherea
target protein is ubiquitinated. For instance, SCF substrates
generallymustbe phosphorylated ﬁrst on the serine residues
(S) of the consensus amino acid sequence motif DSGXXS
before the F-box regulatory subunit can bind the substrate
[43, 65]. Different substrates may be phosphorylated by
different kinases to provide another layer of control, and
the activity of the E3 ligase itself is often regulated by
phosphorylation [105]. Lastly, the subcellular compart-
mentalization of the substrate and E3 ligase may add addi-
tional substrate speciﬁcity. Examples of speciﬁc subcellular
locations include the cell membrane, nuclear and cytoplas-
mic compartments, chromatin, centrosome, mitotic spindle,
and neuronal synapse. Thus, with regard to control of cell
signaling and many biochemical processes, ubiquitination
of speciﬁc substrates is a tightly controlled process that
prevents the random destruction of proteins.
The UPS facilitates diverse biological functions
In addition to its general wastebasket-like function, ubiq-
uitination is also a highly speciﬁc way of controlling protein
expression in signal transduction systems, in cell–cell
communication during development, and at the neural
synapse [113, 147]. Other diverse functions controlled
by the UPS include regulation of gene transcription
via monoubiquitination and deubiquitination of histones,
driving circadian clocks, the auxin-mediated response to
light in plants, and the regulation of cell cycle progression
and apoptosis [26, 113, 131]. The UPS is also important for
the functioning of the immune system and is required for
MHC class I antigen presentation [39, 83, 144].
The UPS in neural development
Notch is an integral membrane protein responsive to
extracellular signals. Notch has been implicated in neural
stem cell proliferation, self-renewal and differentiation
[73]. It has also been implicated in plasticity of adult brain
hippocampus. It is cleaved by c-secretase activity, which
allows its signal transduction component to translocate to
the nucleus and activate transcription. c-Secretase is
derived from the presenilin complex, the constituents of
which are all UPS substrates [82]. Notch protein stability is
also negatively regulated by the SCF ubiquitin ligase.
The SCF ubiquitin ligase substrate b-catenin is a tran-
scription factor that also regulates proliferation of neural
precursor cells. An amazing study by Chenn and Walsh [13]
showed that transgenic mice expressing a stabilized form of
b-catenin in neural precursor cells develop enlarged cere-
bral cortices with complex gyral patterns resembling those
of primates.
Bone morphogenic proteins (BMPs) and Shh proteins
are secreted proteins involved in dorsal–ventral induction
in neurogenesis and other developmental and signaling
processes [37]. The downstream effector proteins of BMP
and Shh, Smad and Gli proteins, respectively, are both
transcription factors regulated by ubiquitin-dependent
proteolysis, as are BMP cell membrane surface receptors
[99]. Furthermore, both Gli proteins and Smad protein
complexes induce transcription of E3 ligase proteins.
Additionally, the APC/C E3 ligase is involved in the reg-
ulation of axonal growth and patterning in the developing
cerebellum [66].
UPS pathology in neurodegenerative disease
Alzheimer disease
Dysregulation of the UPS appears to be both a cause and
result of neurodegenerative disease processes. In Alzheimer
disease, hyperphosphorylation of the microtubule-associ-
ated protein tau results in the accumulation of paired helical
tau ﬁlament involved in the formation of neuroﬁbrillary
tangles and neuritic plaques. These abnormal tau aggregates
are immunoreactive for anti-ubiquitin antibodies suggesting
that the cell is attempting to dispose of these abnormal
proteins. Kinases implicated in tau phosphorylation include
Acta Neuropathol (2009) 118:329–347 333
123those involved in phosphorylation of substrates to allow
recognition by ubiquitin ligases, namely casein kinase 1 and
glycogen synthase kinase 3 (GSK3) which phosphorylate
SCF-b-TrCP E3 ligase substrates [24, 56]. The UPS is also
involved in early stages of autophagy, and neuronal gran-
ulovacuolar degeneration structures are ubiquitin positive
[15, 62]. Relative dysfunction or inhibitory overloading of
the UPS may contribute to the abnormal accumulation of
phosphorylated and ubiquitinated tau. Interestingly, a
frameshift mutant of ubiquitin, UBB?1, found in some
sporadic and hereditary Alzheimer disease and polygluta-
mine repeat disease patients, inhibits the UPS and enhances
toxic protein aggregation in a yeast model system [30, 124].
Indeed anti-ubiquitin antibodies are good, albeit nonspe-
ciﬁc, markers for many of the abnormal cellular inclusions
and neuropil deposits found in Alzheimer disease, cortico-
basal degeneration, progressive supranuclear palsy, Picks
disease, other frontotemporal dementias, multiple system
atrophy, Parkinson disease, amyotrophic lateral sclerosis
and others [15] (Fig. 3).
The relative importance of tau neuronal pathology and
b-amyloid deposition in extracellular plaques in Alzheimer
disease is a perennial topic of debate. b-amyloid is derived
from amyloid precursor protein (APP), a neuronal trans-
membrane protein that appears to function as a cell
membrane receptor and is also involved in synaptic vesicle
recycling [12, 14].
APP binding protein-1 (APP-BP1) binds APP intracel-
lularly at the membrane [14]. APP-B1 also associates with
UBA3 and together they act as an E1-like activating
enzyme for the process of neddylation. The APP-B1/UBA3
complex and the NEDD8 conjugating enzyme Ubc12
appear to be necessary for neddylation of cullin proteins
and normal cell cycle progression from S-phase to mitosis
in Chinese hamster ovary cells [12]. Overexpression of
APP or APP-BP1 in cultured primary rat neurons causes
DNA synthesis and apoptosis by a mechanism dependent
upon the presence of UBA3, Ubc12, and caspase-6 activity.
Similar to Notch, APP is subjected to intramembrane
proteolysis via a presenilin-dependent c-secretase activity.
This results in release of b-amyloid, p3 and the APP
intracellular cleavage domain fragment (AICD). AICD can
translocate to the nucleus and result in apoptosis of cells in
culture. It is postulated that APP-B1-mediated activation of
neddylation, and presumably cullin-based ubiquitin ligases,
signals postmitotic neurons to re-enter the cell cycle trig-
gering their apoptosis similar to AICD [12]. Overexpression
of APP increased APP-BP1 levels in cell membrane lipid
rafts in cultured neurons and increased APP-B1 is found in
lipid rafts in the hippocampus of Alzheimer disease patients
[11]. These ﬁndings suggest that in addition to the role of b-
amyloid deposition in apparently disrupting brain circuitry,
cellular signaling aberrations involving APP-B1 and AICD
resulting in neuronal toxicity and death may be additional
mechanisms of APP-mediated Alzheimer neurodegenera-
tion [61].
p62 is a polyubiquitin binding protein processing UBA-
and UBL-like domains. It may thus act as a receptor/shuttle
Fig. 3 Anti-ubiquitin
immunostaining in
neurodegenerative disease.
Ubiquitin antibodies highlight
Alzheimer disease pathology
including hippocampal plaques
(a) and neuroﬁbrillary tangles
(b). Brain stem (c) and cortical
Lewy bodies (d) are also
ubiquitin positive. Ubiquitin-
positive inclusions are found in
the nucleus of cortical neurons
in Huntington disease (e) and in
the cytoplasm of anterior horn
neurons in motor neuron disease
(f). Original magniﬁcations are
9200 (a, b) and 9400 (c–f)
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123protein capable of transferring polyubiquitinated proteins
such as polyubiquitinated tau to the 26S proteasome. Indeed
p62 can be found associated with tau in neuroﬁbrillary
tangles. p62 appears to bind K63-linked polyubiquitin
chains and promote the clearance of K63-linked polyubiq-
uitinated proteins by autophagy [123]. It also may serve as a
scaffold protein to promote K63-linked polyubiquitination
of membrane proteins by the RING-type E3 ligase tumor
necrosis factor receptor associated factor 6 (TRAF6). p62
also associates with itself and other proteins in a cytoplas-
mic complex known as the sequestosome and may thus be
involved in delivery of proteins to the lysosome (Fig. 4).
A recent study of p62 knock-out mice revealed that adult
animals developed age-dependent hyperphosphorylated tau,
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Fig. 4 Simpliﬁed model of the UPS, endosome–lysosome system and
autophagy cellular pathways. Cell membrane proteins that are UPS
substrates (S) are generally monoubiquitinated and degraded in the
endosome-lysosome system, or polyubiquitinated and delivered to the
26S proteasome by ubiquitin receptor proteins (UR). Nuclear proteins
are degraded in the proteasome within the nucleus or translocated to
the cytosol where they can be degraded by various routes. Polyubiq-
uitinated nuclear proteins may be deposited into neuronal intranuclear
inclusions (NII) in disease states. Polyubiquitinated cytosolic proteins
and UPS machinery proteins such as E2s, E3s and proteasomal
subunits may be transported along microtubules (dotted lines)t ob e
deposited into aggresomes, which may form neuronal cytoplasmic
inclusions (NCI). Similar to other SCF E3 ligase substrates, tau is
probably ﬁrst phosphorylated by casein kinase 1, which facilitates
further phosphorylation by GSK3. Hyperphosphorylated tau is
deposited into neuroﬁbrillary tangles, which like NCIs may be
cleared by autophagy. K63-linked polyubiquitinated chains bind p62
and form complexes known as sequestosomes. Aggregation of
insoluble misfolded proteins is prevented by heat shock proteins
(HSP), which also promote the fusion of sequestosomes to autophagic
vacuoles and ultimately the lysosome
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123neuroﬁbrillary tangles and neurodegeneration and a
behavioral and cognitive phenotype mimicking Alzheimer
disease [104]. Biochemical fractionation revealed K63-
linked polyubiquitinated tau aggregates. p62 therefore binds
with K63-linked polyubiquitinated tau to prevent its
aggregation so that it can be sequestered and delivered to
the lysosome. In support of this pathway, tau binds HSP90,
which may facilitate tau phosphorylation [126], but is also
important in the binding of proteins to the lysosomal
membrane. Interference with this degradative pathway may
produce Alzheimer disease or Alzheimer-like dementia.
Frontotemporal lobar degeneration (FTLD) includes tau
immunopositive and tau immunonegative forms. FTLD
with ubiquitin-immunoreactive lesions (FTLD-U) is a
major type of tau negative FTLD, which can be further
subdivided into TAR DNA binding protein 43 (TDP-43)
immunopositive and immunonegative types [46, 53, 101,
108]. TDP-43 negative FTLD-U subtypes demonstrate
either both nuclear and cytoplasmic ubiquitin-positive
neuronal inclusions or cytoplasmic inclusions only. Cyto-
plasmic, but not nuclear inclusions are also p62 positive
[46]. Thus, p62 is linked to both cytoplasmic ubiquitination
and autophagy in neurons, but may not be involved in
proteasome-mediated degradation of proteins. The latter
may be less important compared to autophagy in Alzhei-
mer disease and frontotemporal dementias.
Parkinson disease
Familial juvenile onset Parkinson’s disease is caused by a
defect in an SCF E3 ubiquitin ligase component known
as parkin (PARK2) (Fig. 2). Substrates of parkin-medi-
ated ubiquitination include a minor glycosylated form of
a-synuclein (a-sp22), the a-synuclein binding protein
synphilin-1, the parkin-associated endothelin receptor-like
receptor (Pael-R) and cyclin E [120]. Along with parkin,
both a-sp22 and Pael-R are found in the Lewy body
cytoplasmic inclusions characteristic of most forms of
Parkinson disease. Overexpression of Pael-R results in the
rapid loss of dopaminergic striatonigral neurons in rats
with no observed effect on GABAergic neurons of the
globus pallidus [25]. Since Pael-R protein would tend to
accumulate in the presence of mutated parkin, this supports
the possible importance of Pael-R in the pathogenesis of
autosomal recessive juvenile Parkinsonism.
Parkin also ubiquitinates the ataxin-2 protein which is
disrupted by expansion of its polyglutamine repeat in spi-
nocerebellar ataxia type 2 [50]. Like the APC/C E3 ligase,
parkin is believed to function as a tumor suppressor protein
[33, 77].
Genes mutated in other forms of autosomal recessive
Parkinson disease include phosphatase and tensin homo-
logue deleted on chromosome ten (PTEN)-induced putative
kinase 1 (PINK1, also known as PARK6) and DJ-1
(PARK7). A recent study has shown that PINK1 and DJ-1
form a complex with parkin and promote parkin’s ubiquitin
ligase activity [142]. Another study showed that parkin
directly interacts with PINK1 and blocks ubiquitin-depen-
dent proteolysis of PINK1 [117]. These studies implicate
dysfunction of parkin E3 ligase activity as a common
etiologic mechanism for recessive forms of inherited
Parkinson disease, all of which may be possibly caused by
over accumulation of Pael-R. PINK1/parkin also appears to
be important in mitochondrial function, which is deﬁcient
in Parkinson disease.
Rare autosomal dominant forms of Parkinson disease in
German and Japanese kindred have been linked to poly-
morphisms in the DUB enzyme known as ubiquitin
carboxy-terminal hydrolase L1 (UCH-L1) [38, 115]. UCH-
L1 is an abundant protein in neurons and can also act as an
E3 ubiquitin ligase when dimerized. In addition to a-syn-
uclein and synphilin-1, Lewy bodies found in most forms of
Parkinson disease contain UCH-LI and mice lacking UCH-
L1 show neurodegeneration [115]. Furthermore, similar to
parkin, overexpression of UCH-L1 leads to aggresome
formation in response to proteasomal inhibition [2].
Aggresomes are organized cellular structures in which
nonfunctional aggregated proteins are shuttled along micro-
tubulesbydynein-dependenttransport[2,67](Fig. 4).Lewy
bodies are though to form by growth or coalescence of per-
inuclear aggresomes. Neurons in general may be more
susceptible to mutations in UPS components such as E3
ligases and DUBs because they have lower overall cellular
UPS activity capacity compared to glia [127].
It has been suggested that ubiquitination and seques-
tration of proteins such as a-synuclein and synphilin-1 in
aggresomes and large cytoplasmic inclusions is a mecha-
nism used by the cell to protect itself from the toxicity of
these proteins [80]. This is plausible considering evidence
that small oligomers of prions can overload the proteasome
and are toxic to the cell [68]. This may also explain why
Parkinson disease occurs in the autosomal recessive form
that harbors defective parkin E3 ligase despite that dopa-
minergic nigral neurons do not develop Lewy bodies in
these patients.
Yet, there is conﬂicting evidence for the pathogenesis of
a-synuclein aggregation. a-Synuclein is mono- and di-
ubiquitinated by the E3 ubiquitin ligase SIAH-1. This
reportedly promotes a-synuclein aggregation and enhances
its neural toxicity [75, 109]. Ubiquitination of synphilin-1
by SIAH-1 also promotes its aggregation into inclusions
[28, 80]. Interestingly, SIAH-1-mediated a-synuclein
ubiquitinization was inhibited by the Parkinson disease-
associated A30P a-synuclein mutation supporting a role for
toxicity of the unaggregated form of mutant a-synuclein in
inhibiting UPS function.
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mutated in about 2–5% of sporadic and autosomal dominant
Parkinson disease, respectively [34, 149]. LRRK2 is ubiq-
uitinated by the E3 ubiquitin ligase carboxy terminus of
Hsc70-interacting protein (CHIP), which associates with
HSP70 [63]. CHIP and parkin both can bind HSP70 and
ubiquitinate polyglutamine repeat expanded proteins such
as ataxin-3 [95]. LRRK2 is found associated with a-syn-
uclein in Lewy bodies and in glial cytoplasmic inclusions in
multisystem atrophy [49]. LRRK2 has been shown to co-
immunoprecipitate with parkin consistent with it also being
a parkin substrate. One study showed that LRRK2 aggre-
gates in LRRK2-transfected cells were increased by parkin
coexpression, which increased ubiquitination of aggregated
LRRK2 [142]. LRRK2 also associates with microtubules
and induces protein aggregation at the cell membrane,
synapses, and membrane-bound organelles suggesting that
it has a physiological role in autophagy. Indeed cytoplasmic
neuronal inclusions resulting from proteasomal inhibition
can be cleared by autophagy in model systems.
Prion diseases
Spongiform encephalopathies such as sporadic and variant
Creutzfeldt–Jakob disease are neurodegenerative condi-
tions caused by mutant hereditary or transmissible prion
proteins. The unique property of prions is their ability to
induce abnormal conformational changes in normal prion
proteins. In some forms of prion disease, e.g., Kuru,
abnormal prion proteins form ubiquitin immunopositive
amyloid plaques. As misfolded mutant proteins patholog-
ical prions are ‘‘born’’ UPS substrates. Although disease-
associated prions are deposited into perinuclear cytoplasmic
aggresomes in prion infected cultured neurons and infected
mouse brains, evidence suggests that prion-mediated neu-
ronal toxicity is due to inhibition of proteasome proteolytic
activity by prion oligomers [68, 69].
Additionalevidencelinkingprionpathologytodisruption
of the UPS has come from mouse models. Mutation of the
RING-type ubiquitin ligase mahogunin results in a spongi-
form encephalopathy in mice histologically mimicking
human prion disease [58]. Mahogunin monoubiquitinates
tumor susceptibility gene 101 (TSG101), a protein involved
in endosomal sorting. Mahogunin knockdown by siRNAs
interferes with endosome to lysosome trafﬁcking of EGFR
receptors in cultured cells. Study of mice strains exhibiting
variable incubation times for prion diseases identiﬁed an E3
ligase known as HECT domain containing 2 (HECTD2) as a
quantitative trait gene associated with decreased disease
incubation periods. Furthermore, analysis of human prion
disease patient samples identiﬁed speciﬁc HECTD2 haplo-
types associated with variant CJD and Kuru, further
implicating a role for HECTD2 ubiquitin ligase in prion
disease [84]. The above studies link both ubiquitin ligase or
proteasome dysfunction and endosome–lysosome dysfunc-
tion to the pathogenesis of prion diseases.
Motor neuron disease
Amyotrophic lateral sclerosis (ALS) is a rapidly progres-
sive fatal motor neuron disease that occurs in sporadic and
inherited forms. Approximately 20% of the familial cases
harbor mutations in superoxide dismutase-1. In ALS, spinal
motor neurons demonstrate ubiquitin immunopositive
cytoplasmic inclusions (Fig. 3). Two recent studies have
revealed that these inclusions are also immunopositive for
TDP-43 in all cases of ALS not associated with superoxide
dismutase-1 mutations [87]. This ﬁnding is accompanied
by decreased normal expression of TDP-43 in the nucleus.
TDP-43 is a DNA binding protein involved in the patho-
genesis of HIV infection and has no known functional role
in the UPS. Its presence in both FTLD and ALS inclusions
strongly indicates a common link in the neurodegenerative
process in these disorders which is at least in part mediated
by the UPS [60, 103]. Furthermore, the amyotrophic lateral
sclerosis/parkinsonism–dementia complex of Guam (ALS/
PDC) shows histopathological overlap with all major types
of neurodegeneration further illustrating the central role
of the UPS in the pathophysiology of neurodegeneration
[91, 122].
ALS2 is mutated in a juvenile autosomal recessive form
of ALS and codes for an endosomal membrane associated
protein involved in endosomal membrane fusion and
endosomal trafﬁcking along microtubules. Mutant ALS2 is
unstable and is rapidly degraded by the proteasome [143].
Thus, like other neurodegenerative conditions, motor neu-
ron disease has been linked to dysfunction of both the
ubiquitin proteasomal and endosome/lysosome systems.
Polyglutamine repeat diseases
Huntington disease
Huntington disease is characterized by expression of toxic
polyglutaminerepeat-expandedmutatedformsoftheprotein
huntingtin and its aggregation in intranuclear and cytoplas-
mic inclusions. These polyglutamine repeat expanded
proteins are degraded by the UPS, components of which are
alsofoundwithintheinclusions,e.g.,ubiquitin,proteasomal
subunits, chaperones and autophagy proteins [30, 51]
(Fig. 3). Decreased UPS function appears to be associated
with huntingtin neuronal toxicity. Although the mechanism
forthisisnotknown[30,140],neuronaltoxicitymay,atleast
in part, be due to synaptic dysfunction [133]. It is possible
that as postulated for other mutant UPS substrates, such as
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inhibits the proteasome machinery allowing toxicity from
over-accumulated mutated huntingtin or other proteins.
Lysine 48-linked polyubiquitin is increased in the brains
of mouse Huntington models and Huntington disease
patients further suggesting proteasome dysfunction [4]. In
cell culture, induction of neuronal death by mutated hun-
tingtin depends on the amount of mutant protein and the
length of the polyglutamine expansion. Neuron death can
occur in the absence of inclusions, which are associated
with increased neuronal survival consistent with toxicity
from unaggregated mutant huntingtin [3]. Interestingly,
p53 binds a p53-responsive element in the huntingtin gene
activating its transcription [29]. This potentially links
huntingtin expression to p53-mediated stress responses and
implicates control of p53 stability as a possible effector of
the expression of mutant huntingtin.
Spinocerebellar ataxias
The spinocerebellar ataxias (SCA) are characterized by
progressive cerebellar ataxia, often accompanied by other
long tract and variable ophthalmic signs [5, 74, 107]. Most
are autosomal dominant disorders and many are mediated
by pathological expansion of polyglutamine repeats within
functional proteins. Spinocerebellar ataxia type 1 (SCA1)
results from polyglutamine repeat expansion of the protein
encoded by the gene ataxin-1. Ataxin-1 protein is a
substrate of the E3 ubiquitin ligase UBE3A and mutant
ataxin-1 is resistant to ubiquitin-dependent proteolysis. An
ataxin-1 interacting protein known as ataxin-1 interacting
ubiquitin-like protein (A1Up) possesses N-terminal UBL
and C-terminal UBA domains [107]. It also contains heat
shock protein chaperonin-binding motifs. Heat shock
chaperones, e.g., HSP70 and HSP90, and chaperonin pro-
teins prevent protein aggregation, especially of misfolded
proteins and are involved in the ubiquitin-dependent deg-
radation of misfolded and otherwise damaged proteins. The
UBL is necessary for A1Up’s association with the 19S
proteasome and this association is inhibited by misfolded
mutant polyglutamine repeat ataxin-1 [107]. Thus, disrup-
tion of the delivery of ubiquitinated ataxin-1 to the
proteasome may account for ubiquitin immunopositive
nuclearinclusionsobservedinPurkinje,pontineandinferior
olive neurons in SCA1. The interaction of ataxin-1 with the
deubiquitinatingenzymeUSP7isalsoweakenedbyataxin-1
mutation. This may additionally contribute to abnormal
accumulation of ubiquitinated mutant ataxin-1 [47].
As previously noted, the SCA2 gene product ataxin-2 is
ubiquitinated by parkin [50]. Ataxin-2 binds membrane-
associated proteins and transmembrane cell surface recep-
tors. A recent study has shown that ataxin-2 can also
associate with endophilin, a protein involved in synaptic
vesicle endocytosis, and the Cbl E3 ubiquitin ligase
involved in membrane receptor internalization [102].
Ataxin-2 thus appears to be involved in endocytic cycling
of membrane proteins.
The polyglutamine expanded mutant protein of SCA3
(Machado–Joseph disease) contains an ubiquitin-interact-
ing motif [5]. Ataxin-3 has been shown to preferentially
bind K63-linked polyubiquitin chains and act as a de-
ubiquitinating enzyme (DUB) [125]. Ubiquitination of
ataxin-3 itself may enhance its deubiquitinating activity.
SCA7 is also a polyglutamine repeat disorder. Ataxin-7
was found to associate with the R85 splice variant of the
Cbl-associated protein (CAP), which contains a nuclear
localization signal domain and is therefore translocated to
the nucleus [74]. Mutant ataxin-7 interferes with the
nuclear translocation of the transcription factor NF-jB
resulting in decreased BCL-X(L) expression and induction
of apoptosis in cultured cerebellar neurons [132]. Both
translocation of NF-kB to the nucleus and the nuclear
activity of NF-jB are dependent on the ubiquitin-mediated
destruction of inhibitors of jB (IjBs). More recently
ataxin-7 mutants have been shown to inhibit gene tran-
scription and proteasome activity [121, 132]. Inhibition of
NF-jB-mediated gene transcription by mutant, polygluta-
mine repeat expanded ataxin-7 can therefore be explained
by its apparent ability to inhibit ubiquitin-dependent pro-
teolysis. Ataxin-7 mutants may selectively interfere with
the UPS-mediated degradation of proteins bound for the
nucleus.
The above-mentioned SCA types all involve mutation of
UPS component proteins (Table 1). Thus, this group of
diseases associated with similar clinical manifestations
appears to be linked by unique disruptions of the UPS,
particularly with regard to turnover of membrane and/or
synaptic proteins in SCA2 and nuclear proteins in SCA1
and SCA7. Mutant ataxin-2 may also inhibit parkin possibly
contributing to the SCA2 disease process. SCA3 appears to
differ in that the role of ataxin-3 in the deubiquitination
of K63-linked ubiquitin chains suggests dysregulation of
autophagy.
Angelman, Prader–Willi, Rett and Autism
Angelman syndrome is characterized by microcephaly,
severe developmental delay, seizures, ataxia, a stereotypical
hand ﬂapping, and a happy excitable demeanor. It is asso-
ciatedwithdeletionsofchromosomalsegment15q11-13and
is caused by loss of function of the ubiquitin ligase alter-
nately known as UBE3A or E6AP. UBE3A is the same E3
ligase that mediates the human papillomavirus E6 protein-
induced ubiquitination of the p53 tumor suppressor protein.
LossormutationofthematernallyinheritedUBE3Aalleleis
sufﬁcient to cause Angelman disease [111]. Differences in
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UBE3A alleles are due to differential gene methylation
(imprinting). Unlike paternally derived UBE3A, maternal
UBE3A is active in the cerebellum and hippocampus. It is
needed to maintain CA1 synaptic plasticity, which is lost in
UBE3A
-/- mice and is necessary for normal experience-
based maturation of the visual cortex [146]. Known sub-
stratesofUBE3Ahavenotbeenlinkedtothepathogenesisof
Angelman syndrome. The disease can be prevented, how-
ever, in an Angelman mouse model by mutation of the
inhibitory phosphorylation site of the alpha subunit of
calcium-calmodulin-dependentproteinkinaseII(a-CaMKII),
suggesting Angelman syndrome may result from increased
inhibitory phosphorylation of a-CaMKII [27]. The impor-
tant target of UBE3A in Angelman disease may thus be a
direct or indirect regulator of a-CaMKII phosphorylation.
Since a-CaMKII is also important in maintaining hippo-
campal plasticity, this is a highly plausible hypothesis [27].
Prader–Willi syndrome, characterized by hyperphagia,
cognitive impairment and hypogonadism, results from loss
of genetic material from the same chromosomal region as
in Angelman, but differs in that the paternally derived
segment is lost. UBE3A has not been associated with
Prader–Willi in which multiple different genes have been
implicated. A common misconception is that Angelman
and Prader–Willi are the same disease manifesting differ-
ently in the two sexes. They are of course genetically
distinct disorders and both can occur in either boys or girls.
Rett syndrome shows similar clinical manifestations to
Angelman including microcephaly, cognitive impairment,
hypotonia, seizures, ataxia and abnormal hand movements;
however, it occurs nearly exclusively in girls. Misdiagnoses
Table 1 UPS components and substrates in neuropathological diseases
Disorder Gene product and function
Parkinson disease
Autosomal dominant (early onset) a-Synuclein (SNCA) (PARK1), aggregates in Lewy bodies
Autosomal dominant (late onset) Leucine-rich repeat kinase 2 (LRRK2) (PARK8), a CHIP ubiquitin ligase substrate,
contains a Roc domain as found in SCF ligases
Autosomal dominant (late onset) Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) (PARK5), a DUB, acts as an E3
ligase when dimerized, polymorphisms linked to rare forms of familial disease
Autosomal recessive (juvenile onset) Parkin (PARK2), a subunit of a SCF E3 ubiquitin ligase
Autosomal recessive (early onset) PINK1 (PARK6), promotes parkin ubiquitin ligase activity
Autosomal recessive (early onset) DJ-1 (PARK7) chaperone, promotes parkin ubiquitin ligase activity
Spinocerebellar ataxias
SCA1 Ataxin-1, a UBE3A E3 ligase, mutation blocks its ubiquitination and association with
the ubiquitin receptor A1Up and the DUB enzyme USP7
SCA2 Ataxin-2, associates with c-Cbl E3 ligase and is involved in membrane protein
endocytosis, and is a parkin E3 ligase substrate
SCA3 Ataxin-3, a deubiquitinating enzyme (DUB)
Prion diseases Prions may block normal function of the proteasome, HECT2D E3 ubiquitin ligase
haplotypes are associated with vCJD and Kuru
Autosomal recessive ALS ALS2, an endosomal membrane associated protein involved in endosome membrane
fusion and trafﬁcking, mutation decreases ALS2 protein stability
Angelman syndrome Loss or mutation of UBE3A E3 ligase at Angelman/Prader–Willi locus
Rett syndrome Decreased UBE3A E3 ligase due to MECP2 mutations
Autism Copy number alterations of UBE3A and other UPS genes
Giant axon neuropathy Mutation of gigaxonin, an E3 ubiquitin ligase
IBMPFD Mutation of valosin-containing protein (VCP), involved in ubiquitin-mediated
processing of membrane and cytosolic proteins.
Sporadic IBM VCP and ubiquitin are found in inclusion bodies.
von Hippel–Lindau disease pVHL, substrate-binding subunit of ubiquitin ligase targeting HIF1-a
Medulloblastoma Overexpression of several signaling pathway genes that are ubiquitinated by the SCF:
c-myc, b-catenin, Gli, stabilizing mutations of Gli and b-catenin prevent their
ubiquitin-dependent proteolysis
Adamantinomatous craniopharyngioma Stabilizing b-catenin mutations preventing its ubiquitin-dependent proteolysis
Gliomas Misregulation and mutation of cell cycle control proteins regulated by the UPS: CDKs,
CDK inhibitors, p53, altered expression of APC/C E3 ubiquitin ligase regulators
Emi1 and RASSF1A
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uncommon. Unlike Angelman, Rett patient behavior is char-
acterized by frequent loss of speech and other previously
attained skills, and poor socialization similar to autism. Most
cases are due to sporadic mutations of methyl-CpG-binding
protein-2(MECP2)onthe X chromosome. Malefetuseswith
the mutation are usually nonviable or die before 2 years of
age.Survivingmalesare46,XXY.MECP2bindsmethylated
DNA and acts as a transcriptional repressor and its mutation
can lead to disruption of methylation imprinting of the
UBE3A gene [88]. Decreased UBE3A has indeed been
observedinthebraintissueofMECP2-deﬁcientmiceandRett
syndrome patients.
Further evidence of the global importance of UBE3A,
other ubiquitin ligases and related UPS proteins in cogni-
tive function has come in a very recent publication
identifying these proteins along with neuronal adhesion
proteins as exhibiting copy number variation in a cohort of
over 800 patients suffering from autism spectrum disorders
[36]. UBE3A dysfunction appears to produce a large
spectrum of pediatric cognitive functional levels depending
on the mechanism and severity of UBE3A loss, i.e., autism
to Rett to Angleman syndromes.
The UPS in diseases of the PNS and skeletal muscle
The UPS appears be involved in the initiation of Wallerian
degeneration and a side effect of proteasomal inhibitors is
peripheral neuropathy [148]. Altered ubiquitin-dependent
degradation of Schwann cell proteins may contribute to the
pathogenesis of certain neuropathies [32]. In the Trembler J
mouse model of Charcot–Marie–Tooth disease type 1A
demyelinating neuropathy the turnover rate of nascent
peripheral myelin protein 22 (PMP22) is decreased. These
animals show proteasome impairment correlating with
increased levels of polyubiquitinated PMP22 in nerves [32].
Giant axon neuropathy is a severe autosomal recessive
motor and sensory disorder presenting in infants and children
thatisassociatedwithdisruptionofneuroﬁlaments[145].Itis
causedbythemutationofanubiquitinligasesubstrateadapter
known as gigaxonin, which targets the light chain of micro-
tubule-associated protein 1B (MAP1B), MAP8 and the
tubulin folding chaperone tubulin folding cofactor B (TBCB)
[1]. MAP1B over accumulation is toxic to neurons although
themechanismofneuroﬁlamentdisruptionisnotknown[16].
A signiﬁcant rare untoward effect of statin-type cho-
lesterol lowering drugs such as atorvastatin is a necrotizing
myopathy often accompanied by an inﬂammatory
response, so called statin-induced myopathy. Selective
vulnerability of type IIb muscle ﬁbers occurs in statin-
induced myopathy [135]; however, the precise pathophys-
iologic mechanisms of the condition remain poorly
understood. Mitochondrial dysfunction has been implicated
because statins inhibit both cholesterol and ubiquinone
synthesis. The latter can potentially interfere with mito-
chondrial oxidative phosphorylation.
Increased turnover of muscle proteins by the UPS may be
importantintheactivationofeventsthatleadtostatin-induced
myopathy. The muscle-speciﬁc F-box protein MAFbx (atro-
gin-1) is part of a SCF E3 ligase induced in muscle atrophy.
Hanai et al. [42] found that MAFbx is also induced by lo-
vostatinandthatknockdownofMAFbxpreventedlovastatin-
induced muscle damage in zebraﬁsh embryos. SCF-MAFbx
targets the muscle transcription factor MyoD [110]. MyoD is
importantinbothmuscledevelopmentandmaintenanceofthe
differentiated phenotype of type IIb ﬁbers. MAFbx gene
silencingbyRNAinterferenceinhibitsMyoDproteolysisand
expression of a stabilized K133R MyoD mutant not recog-
nized by SCF-MAFbx prevents atrophy of mouse skeletal
muscle ﬁbers in model systems [72]. These ﬁndings support
thehypothesisthatincreasedubiquitinationofskeletalmuscle
proteins, particularly MyoD, may be an important ﬁnal com-
mon pathway in toxic myopathies caused by statins, and
perhaps other drugs.
Overloading or other perturbations of ubiquitin-depen-
dent proteolysis are probably involved in inclusion
myopathies, such as inclusion body myositis, the myoﬁber
inclusions of which are strongly ubiquitin immunopositive.
IBM degenerating ﬁbers contain hyperphosphorylated tau
and casein kinase 1a, a kinase that phosphorylates tau and
other SCF E3 ligase substrates [56].
Hereditary inclusion body myopathy with Paget disease
of bone and frontotemporal dementia (IBMPFD) is a rare
autosomal dominant disease associated with mutations in
the gene encoding valosin-containing protein (VCP) [134].
VCP is a chaperone protein involved in the ubiquitin-
dependent degradation of membrane and cytoplasmic
proteins and in translocation of misfolded proteins from the
endoplasmic reticulum into the cytoplasm for proteasomal
degradation [96, 137]. As a chaperone, VCP prevents
aggregation of UPS substrates prior to their presentation to
the proteasome [118, 138]. Frontotemporal dementia is
further linked to IBM by the ﬁnding of TDP-43 immuno-
positive sarcoplasmic inclusions in both IBMPFD and
sporadic IBM muscle [134]. Additionally, VCP is also
found in inclusions of both IBMPFD and sporadic IBM.
The UPS in CNS tumors
von Hippel–Lindau disease
Perhaps the most direct example of misregulation of
the UPS in the etiology of neurological tumors is in the
vascular tumors of the hereditary cancer syndrome von
Hippel–Lindau disease (VHLD) [54]. In VHLD, CNS and
340 Acta Neuropathol (2009) 118:329–347
123retinal hemangioblastomas grow in response to overex-
pression of vascular endothelial growth factor (VEGF).
VEGF transcription is driven by hypoxia-inducible factor-
1alpha (HIF-1a). pVHL protein is the substrate recognition
component of the ubiquitin ligase that ubiquitinates HIF-1a
[17] (Fig. 2). The mutant form of pVHL in VHDL is
unable to ubiquitinate HIF-1a leading to its over accumu-
lation. This in turn results in increased VEGF transcription,
promoting the formation of vascular tumors. VHLD
patients also often develop pheochromocytoma, pancreatic
carcinoma and clear cell renal cell carcinoma, and pVHL is
mutated in most sporadic clear cell renal cell cancers.
Thus, the von Hippel–Lindau ubiquitin ligase complex acts
as a tumor suppressor by indirectly regulating levels of the
growth-promoting signal VEGF.
p53 and PTEN
Thetumorsuppressorsp53andPTENarecommonlymutated
inhumanneoplasmsincludingglialtumors,particularlyhigh-
grade astrocytomas and secondary glioblastomas. The p53
protein has many functions within the cell [7, 19–21, 70]. Its
mostwell-describedfunctionsareinthetriggeringoftheG1/S
checkpoint and induction of apoptosis. p53 activation of
INK4a gene results in transcription of the cyclin-dependent
kinase inhibitor p16 which interferes with the ability of these
kinases to phosphorylate and inactivate the pRb tumor sup-
pressor. p53 also induces transcription of the BAX family of
proteins responsible for inducing apoptosis via disruption of
the mitochondrial membrane, and may initiate apoptosis by
direct interaction with mitochondria in the cytosol. Loss of
p53 function may thus lead to uncontrolled cellular prolifer-
ation by allowing unregulated cell cycling through the G/S
checkpoint.Itmayalsocontributetosurvivalandproliferation
ofgeneticallydamagedcellsbyremovingthesignaltoinitiate
apoptosis in such cells. Thus, p53 loss is thought to be a key
mechanism in tumorigenesis.
A persistent misconception is that positive nuclear p53
immunohistochemical reactivity indicates p53 mutation.
p53 transcription is induced by several forms of cellular
stress and nuclear p53 reactivity can be detected in both
benign and malignant cells with wild-type p53. However,
some p53 mutants are resistant to ubiquitin-dependent
degradation rendering them inherently more stable than
wild-type p53 protein. Such mutants tend to accumulate,
enabling their detection by immunohistochemical staining.
Human double minute 2 (HDM2) (homologous to MDM2
in mice) is transcriptionally induced by p53, and is an E3
ubiquitin ligase targeting p53. p14
ARF (homologous to the
mouse p19
ARF) is encoded by the INK4a locus induced by
p53. p14
ARF binds HDM2 and prevents its association with
p53. Loss of p14
ARF therefore leads to uninhibited HDM2
mediated p53-ubiquitination and functional loss of p53.
The AKT (protein kinase B) pathway is activated by the
phosphorylation of AKT kinases by phosphoinositide-
dependent kinase (PDK). Among their many functions
AKT serine–threonine kinases inhibit apoptosis by phos-
phorylation of the pro-apoptotic BCL-2/BAX family
protein BAD, and thus promote tumor cell survival. PTEN
is a lipid phosphatase that inhibits the AKT pathway by
dephosphorylating phosphatidylinositol (3,4,5)-trisphos-
phate (PIP3), the phosphate donor used by PDK. PTEN
loss in tumors thus leads to upregulation of the AKT
activating pathway.
Research has also uncovered a link between PTEN
and p53 destruction. PTEN inhibits HDM2-mediated p53
destruction (or translocation) in the cell nucleus. Speciﬁ-
cally, through inhibition of the AKT pathway, PTEN
inhibits the translocation of HDM2 from the cytoplasm to
the nucleus [90]. PTEN loss therefore leads to increased
ubiquitination of nuclear p53. The resultant decreased
nuclear p53 protects tumor cells from DNA damaging
chemotherapy [76, 90]. PTEN is ubiquitinated by the
pro-oncogenic HECT-type E3 ligase Nedd4-1. Thus, in
addition to p53 stabilizing mutations, loss of the UPS
regulatory and functional components p14
ARF, HDM2 and
PTEN may lead to p53 misregulation in tumors.
SCF ubiquitin ligase targets and medulloblastoma
Medulloblastoma is the most common pediatric brain tumor
and is thought to arise from cerebellar neural progenitor
cells. b-catenin protein binds TCF and LEF transcription
factors resulting in transcription of several genes, and has
been shown to regulate neural progenitor cell proliferation.
Transgenic mice overexpressing b-catenin in the CNS
developed enlarged brains because a greater number of their
periventricular neural progenitor cells re-entered the cell
cycle[13].Up-regulationoftheb-cateninsignalingpathway
occurs in many human neoplasms. It has been most widely
recognized in colon tumors, particularly in familial adeno-
matosus polyposis coli syndrome, but has also been
implicated in medulloblastomas. The adenomatous polyp-
osis coli (APC) protein is an essential participant in the
ubiquitination of b-catenin. Like other SCF target proteins,
b-catenin must be phosphorylated before it can be recog-
nized by the SCF. APC is essential for this to occur.
Together with the protein axin, APC is thought to act as a
scaffold necessary for the binding and phosphorylation of
b-cateninbyGSK3.APCmutationsthus preventphosphory-
lation and subsequent ubiquitin-dependent degradation of
b-catenin. Mutated b-catenin resistant to phosphorylation by
GSK3 is therefore abnormally stabilized. Such mutations
are found in some sporadic colon cancers, some medullo-
blastomas and adamantinomatous craniopharyngiomas [9,
114]. Interestingly, c-Myc, Notch and Gli (a downstream
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dysregulated in medulloblastomas, and like b-catenin,
all are involved in brain development and are regulated
by SCF-mediated ubiquitin-dependent proteolysis. This
suggests that SCF controlled signaling pathways are par-
ticularly important in controlling the fate of cerebellar stem
cells. Patch, a negative regulator of Shh signaling, is also
mutated in medulloblastoma, but appears to ubiquitinated
by the Nedd4 E3 ligase [23, 85].
Anaphase promoting complex/cyclosome pathway
The anaphase promoting complex/cyclosome (APC/C) (not
to be confused with the fore mentioned APC protein) is an
E3 ubiquitin ligase that ubiquitinates several important cell
cycle regulatory proteins. The APC/C is associated with
two different activator subunits that impart general sub-
strate speciﬁcity, Cdh1 and Cdc20 (Fig. 2). The APC/C
regulates the ubiquitin-dependent degradation of several
proteins that drive the cell cycle including cyclins A and B.
The APC/C substrates geminin, survivin, polo and aurora
kinases are overexpressed in ependymomas and high-grade
gliomas [35, 77]. Securin or pituitary tumor transforming
gene-1 (PTTG-1) is an APC/C target frequently overex-
pressed in pituitary adenomas and is a key component of
the mitotic spindle checkpoint, which controls the initiation
of chromosome segregation at the metaphase plate of
dividing cells. Securin inhibits an enzyme that initiates
chromosome segregation known as separase. Upon for-
mation of a mature metaphase mitotic spindle the APC/C
ubiquitinates securin. This results in release of separase
inhibition and segregation of chromosomes to daughter
cells. Radiation or microtubule destabilizing drugs such as
pacitaxel can interfere with the checkpoint and arrest cell
division. Overexpression or knockdown of levels of APC/C
substrate proteins leads to genomic instability and cellular
neoplastic transformation [77, 79]. The APC/C also acts as
a tumor suppressor by regulating the levels of these cell
cycle proteins.
Emil protein is a pseudosubstrate inhibitor of the APC/C
and is overexpressed in ependymomas and high-grade
astrocytomas [48, 77, 93, 105]. Emi1 regulates APC/C E3
ligase activity during S-phase and early mitosis [48, 130].
The protein product of the RASSF1A gene takes over the
negative regulation of APC/C activity following the SCF-
mediated ubiquitin-dependent degradation of Emi1 in early
mitosis [119]. The RASSF1A gene is silenced by promoter
methylation in a large percentage of glial tumors and
medulloblastomas [45, 86, 92]. Thus, dysregulation of the
APC/C pathway may be a common feature of glial tumors.
An interesting form of biochemical crosstalk occurs
between the SCF and APC/C ubiquitin ligases. p27 is a
cyclin-dependent kinase inhibitor whose ubiquitin-depen-
dent degradation serves as an important trigger to allow
both the G1/S and G2/M cell cycle transitions. Ubiquiti-
nation of p27 is accomplished by the SCF E3 ligase
complexed with the F-box protein Skp2. Skp2 is in turn
ubiquitinated by the APC/C. Tumors overexpressing Skp2,
e.g., because of dysregulated Emi1 over-inhibiting the
APC/C, tend to have defective regulation of the G1/S or
G2/M transitions due to heightened targeting of p27 by
SCF
Skp2 [78] (Fig. 5).
Skp2 - p27 +
Fig. 5 Cross-talk between the SCF and APC/C regulates cell cycle
progression. The SCF E3 ubiquitin ligase F-box adapter protein Skp2
is expressed at levels undetectable by immunohistochemistry in
benign schwannomas while its target the cyclin-dependent kinase
inhibitor p27 is expressed at detectable levels. Skp2 is a substrate
target of the APC/C-Cdh1 E3 ligase, the activity of which may be
decreased in many malignant tumors. The opposite pattern of p27 and
Skp2 expression may therefore be found in malignant neoplasms [77,
78]. Immunostained tissue microarray cores are shown (9100)
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Several proteasome inhibitors have undergone clinical
trials as anti-cancer agents. The proteasome inhibitor
bortezomib (PS-341) has been approved for the treatment
of multiple myeloma and mantle cell lymphoma [106].
Bortezomib is thought to have many pharmacological
effects including inducing aggresome formation; however,
its antineoplastic action may be attributable to induction of
apoptosis. This may deﬁne a mechanistic pathway of drug
action because aggresome formation can itself lead to
apoptosis.
A pharmacologic inhibitor of the HDM2 E3 ubiquitin
ligase targeting p53, known as MI-63, showed antiprolifer-
ative activity and induction of apoptosis in mantle cell
lymphoma cells, and was synergistic with rapamycin and
bortezomib in vitro [52]. SCF and APC/C E3 ligases are
intriguing additional possible pharmacological targets.
Small molecule inhibitors of the APC/C substrates aurora A
and aurora B kinases have shown antineoplastic activity in
animal tumor models and several are currently in clinical
trials [89, 128]. Some of these anti-UPS drugs or novel
agents targeting other components of the UPS may eventu-
ally prove efﬁcacious against CNS neoplasms. For instance,
aurora A (STK15) expression was found to be an indepen-
dent predictor of survival in medulloblastoma [100].
In situations where UPS components are mutated, as in
autosomal recessive forms of Parkinson disease and Ang-
elman disease, gene therapy to replace the speciﬁc lost E3
ligase activity may be possible in the future. New therapies
for disease in which mutant misfolded proteins are pro-
duced such as polyglutamine repeat disorders may be
particularly challenging. Anti-aggresome therapy for all
neurogenerative diseases involving abnormal protein
accumulation has also been postulated. One general form
of such therapy would be potentiation of the UPS, which
has been proposed to treat neurodegenerative diseases.
Finkbeiner and Mitra [30] warn that such treatment would
have to target components speciﬁc to UPS-mediated deg-
radation of speciﬁc substrates, or perhaps groups of
substrates to prevent numerous potential off target effects.
An interesting study showed that the anti-acidosis drug
benzamil enhanced UPS activity, and that blocking the
expression of an isoform of the drug’s target the acid-
sensing ion channel also enhanced UPS activity and
decreased mutant huntingtin aggregation in the brains of a
mouse model of Huntington disease [140]. Other potential
drug targets might be components of the UPS relatively
speciﬁc to neurons such as synaptic endocytosis factors,
ubiquitin-like proteins, E2 Ubc’s or E3 ligases. Small
changes in the activity of such factors might selectively
affect neurons because of their lower overall UPS capacity
compared to glia [127]. One possible candidate target is
UBE3A. Mutation or loss of function of UBE3A and or its
substrates is found in Angelman syndrome, Rett syndrome,
autism and SCA1 (Table 1). Overexpression of UBE3A
protected against the toxicity of polyglutamine repeat
expanded proteins in models of Huntington disease and
spinocerebellar ataxia [94]. Thus, UBE3A potentiating
therapy may be a means to treat multiple polyglutamate
repeat diseases as well as Angelman and Rett syndromes
and autisms. A possible approach would be to screen for a
compound that inhibits the phosphorylation and/or sub-
sequent ubiquitination of UBE3A. In the absence of small
molecule potentiators or gene therapy, perhaps intrathecal
delivery of UBE3A might be transiently effective. Since
viral E6 can activate UBE3A to target p53, this suggests an
intriguing possibility of rationally designed viral-mediated
therapy to target other UBE3A substrates.
A different approach might have to be taken for tau-
opathies, ALS and Parkinsonian conditions which show
some commonalities in their UPS pathology. Pharmaco-
logic strategies have been proposed for Parkinson disease
based on the effects of the LRRK2 mutation. Reduction in
LRRK2 results in decreased neuronal toxicity. Such a
reduction could be achieved by antagonizing the protective
role of HSP90 in blocking LRRK2 ubiquitination by CHIP
E3 ligase [63]. Since many neurodegenerative cytoplasmic
inclusions can be cleared by autophagy, upregulation of
autophagy has been proposed as a general treatment for
Parkinson diseases, polyglutamine repeat disorders, and
tauopathies [136]. c-Secretase inhibitors are in clinical
trial for Alzheimer disease and effectively lower serum b-
amyloid [31, 139]. Because the same c-secretase that acts
on APP also acts on Notch, c-secretase inhibition results in
some off target effects, namely alterations in lymphopoesis
and intestinal epithelial cell differentiation [139].
Summary
Research into the possible and established roles of com-
ponents of the UPS in human diseases, particularly in
neurological disorders, is appearing in the literature in an
explosive manner. Common themes of UPS disruption are
emerging in related disorders such as among the autosomal
recessive forms of Parkinson disease, the spinocerebellar
ataxias, and the cognitive disorders Angelman disease, Rett
syndrome and autism.
This review covers only basic UPS components and
provides simpliﬁed overviews of speciﬁc UPS-related dis-
eases. New levels of biochemical, genetic and epigenetic
regulation of the UPS, as well as new interconnections
between UPS regulated signaling pathways are continually
being discovered. The UPS and its substrates are thus topics
of growing complexity. Yet there is little doubt that the UPS
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123and its components will come to represent key factors in our
future understanding, diagnosis and perhaps even treatment
of neuropathological diseases. The discovery of disease
producing defects in the UPS will likely lead to routine
molecular subtyping of neurodegenerative, myopathic,
neuropathic and neoplastic diseases. Some of these defects
might be detectable by simple immunohistochemical
methods, e.g., when a protein is absent, overexpressed, or
sequestered in aggresomes. In some instances the neuro-
pathologist may be responsible for providing proper
neuropathological context and tissue samples to the
molecular pathologist, e.g., for gene mutational or methyl-
ation status analysis. Familiarity with the basic components
of the UPS and knowledge of UPS defects in neurological
diseases will deﬁnitely be of future importance in
neuropathology.
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